Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy
Christophe Hézode,1 Paul Kwo,2 Jan Sperl,3 Peggy Hwang,4 Jianmin Long,4 Rohit Talwani,4 Michael N Robertson,4 Barbara A Haber4 1Service d’Hépatologie, Hôpital Henri-Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, France; 2Div...
Main Authors: | Hézode C, Kwo P, Sperl J, Hwang P, Long J, Talwani R, Robertson MN, Haber BA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-11-01
|
Series: | International Journal of Women's Health |
Subjects: | |
Online Access: | https://www.dovepress.com/elbasvirgrazoprevir-in-women-with-hepatitis-c-virus-infection-taking-o-peer-reviewed-article-IJWH |
Similar Items
-
Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
by: Sulejmani N, et al.
Published: (2018-05-01) -
FIXED PROLONGED REGIME OF COMBINED ORAL CONTRACEPTIVES (COC) INTAKE IN SOLUTION OF CLASSIC CONTRACEPTION ISSUES (LITERATURE REVIEW)
by: V. N. Prilepskaya, et al.
Published: (2017-07-01) -
Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse
by: Bonsall D, et al.
Published: (2018-08-01) -
Investigation of plant flavonoids as potential dengue protease inhibitors
by: Mangala K Jayadevappa, et al.
Published: (2020-10-01) -
Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors
by: Luciana Bonome Zeminian, et al.
Published: (2013-02-01)